We therefore provided functional evidence that HYAL1 is oncogenic for breast cancer and functional antagonism of HYAL1 constitutes a potential therapeutic strategy for HYAL1 positive breast cancer. The gene discussed is HYAL1; the disease is breast carcinoma.